By Stephen Nakrosis 
 

Regeneron Pharmaceuticals, Inc. on Monday said it finalized a restructuring of its Praluent agreements with Sanofi.

The company said the restructured agreements, which were effective April 1, call for Regeneron to have sole responsibility for Praluent and record net product sales in the U.S. Sanofi will have sole responsibility outside the U.S. and pay Regeneron a royalty on Praluent net product sales, the company said.

Praluent is indicated to reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease, and also for the treatment of adults with primary hyperlipidemia to reduce low-density lipoprotein cholesterol, Regeneron said.

 

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

April 06, 2020 19:27 ET (23:27 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From May 2020 to Jun 2020 Click Here for more Regeneron Pharmaceuticals Charts.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2019 to Jun 2020 Click Here for more Regeneron Pharmaceuticals Charts.